Henoch-Schönlein Purpura

Comprehensive Clinical Guide: Henoch-Schönlein Purpura (IgA Vasculitis)

1. Introduction and Clinical Overview

Henoch-Schönlein Purpura (HSP), now more accurately termed IgA Vasculitis (IgAV), represents the most common form of systemic vasculitis in the pediatric population. It is a small-vessel, immune-complex-mediated vasculitis characterized by the deposition of immunoglobulin A (IgA1)-dominant immune complexes in the vessel walls.

While predominantly a pediatric condition—with a peak incidence between ages 3 and 10—it can manifest in adolescents and adults, where it typically presents with a more aggressive clinical course and higher risk of renal impairment. The classic clinical tetrad includes palpable purpura, arthralgia/arthritis, abdominal pain, and renal involvement. Understanding the pathophysiology and the potential for long-term morbidity is critical for any orthopedic or clinical practitioner.

2. Etiology and Pathophysiology

The precise trigger for IgA Vasculitis remains multifactorial, involving a complex interplay between genetic predisposition, environmental triggers, and aberrant immune responses.

The Mechanism of Action

1. Antigenic Trigger: The process is often preceded by an upper respiratory tract infection (URI), particularly Streptococcus pyogenes, or exposure to certain medications, vaccinations, or insect bites.
2. IgA1 Aberration: Patients often exhibit elevated serum levels of galactose-deficient IgA1 (Gd-IgA1). This defect prevents proper O-glycosylation in the hinge region of the IgA1 molecule.
3. Immune Complex Formation: The body produces autoantibodies (IgG or IgA) directed against these galactose-deficient IgA1 molecules. These form large, circulating immune complexes.
4. Vascular Deposition: These complexes deposit in the walls of small vessels (arterioles, capillaries, venules), specifically in the skin, gastrointestinal tract, joints, and kidneys.
5. Complement Activation: The deposition triggers the alternative complement pathway, leading to the recruitment of neutrophils, release of inflammatory cytokines, and subsequent endothelial damage (leukocytoclastic vasculitis).

3. Clinical Indications and Presentation

The clinical presentation is highly variable, but the following features are diagnostic hallmarks.

Clinical Staging and Grading (Renal Involvement)

Given that renal involvement determines long-term prognosis, the International Study of Kidney Disease in Children (ISKDC) grading system is often utilized for biopsy specimens:

• Grade I: Minimal change or minor mesangial proliferation.
• Grade II: Pure mesangial proliferation (focal or diffuse).
• Grade III: Mesangial proliferation with crescents < 50%.
• Grade IV: Mesangial proliferation with crescents 50–75%.
• Grade V: Mesangial proliferation with crescents > 75%.
• Grade VI: Membranoproliferative pattern.

4. Differential Diagnosis

Because the presentation can mimic other systemic diseases, the following must be ruled out:

• Hypersensitivity Vasculitis: Usually drug-induced; lacks IgA deposition.
• Systemic Lupus Erythematosus (SLE): Identified via ANA, anti-dsDNA, and hypocomplementemia.
• Idiopathic Thrombocytopenic Purpura (ITP): Characterized by low platelet counts (HSP has normal platelets).
• Meningococcemia: A medical emergency; involves fever, rapidly progressive purpura, and sepsis.
• Post-Streptococcal Glomerulonephritis: Often follows a latent period post-infection; lacks the purpuric rash.

5. Key Diagnostic Tests

There is no single "gold standard" laboratory test for IgA Vasculitis. Diagnosis is primarily clinical, based on the EULAR/PRINTO/PRES criteria.

1. Laboratory Markers:
   • CBC: To rule out thrombocytopenia (platelets are normal in IgAV).
   • Urinalysis/Microscopy: Essential to monitor for hematuria/proteinuria.
   • Serum Creatinine/BUN: To assess baseline renal function.
   • IgA Levels: Often elevated, though not diagnostic.
2. Imaging:
   • Abdominal Ultrasound: Indicated if intussusception is suspected (common in children).
   • Renal Ultrasound: To assess for structural abnormalities if renal function is compromised.
3. Histopathology (Skin/Kidney Biopsy):
   • Skin: Punch biopsy showing leukocytoclastic vasculitis with IgA deposition on immunofluorescence.
   • Kidney: Indicated for severe or persistent proteinuria/nephrotic syndrome.

6. Risks, Side Effects, and Contraindications

Management focuses on symptomatic relief, but clinicians must be vigilant regarding pharmacological interventions:

• NSAIDs: Often used for arthralgia, but must be used with caution in patients with active renal involvement or gastrointestinal bleeding.
• Corticosteroids: Prednisone is used for severe GI pain or severe renal involvement. However, it does not prevent the development of renal disease.
• Immunosuppressants: Cyclophosphamide, azathioprine, or rituximab may be required for refractory cases or severe crescentic glomerulonephritis.
• Contraindication: Avoid anticoagulants unless specifically indicated for thromboembolic complications, as they may exacerbate gastrointestinal hemorrhage.

7. Long-Term Prognosis

For the majority of pediatric patients, IgA Vasculitis is a self-limiting condition that resolves within 4–8 weeks. However, the risk of recurrence exists in approximately 30% of cases.

Chronic Renal Failure (CRF): The primary long-term risk. Patients with persistent proteinuria or hematuria are at risk for progressive renal damage. Long-term follow-up (up to 12 months post-recovery) is mandatory to ensure the resolution of urinary abnormalities.

8. Frequently Asked Questions (FAQ)

1. Is Henoch-Schönlein Purpura contagious?
No. It is an autoimmune-mediated condition triggered by the body’s reaction to an infection, not an infectious disease itself.

2. Can adults get IgA Vasculitis?
Yes. While it is a pediatric disease, adults can be affected. Adult cases are typically more severe, with a higher incidence of renal failure and hypertension.

3. Why are platelet counts normal in this condition?
Unlike other purpuras (e.g., ITP) caused by low platelets, IgAV is a vasculitis. The purpura is caused by inflammation of the vessel wall, not by a clotting deficiency.

4. What is the most dangerous complication?
Intussusception (bowel telescoping) is a major surgical emergency in the GI tract, while progressive crescentic glomerulonephritis is the major long-term renal threat.

5. Does the rash leave scars?
Usually, the purpura fades within a few weeks without scarring, though residual hyperpigmentation can occur.

6. Is a kidney biopsy always necessary?
No. A biopsy is reserved for patients with severe proteinuria, nephrotic syndrome, or evidence of rapidly progressive renal failure.

7. How long should a patient be monitored?
Patients should undergo monthly blood pressure checks and urinalysis for at least 6 months after the initial diagnosis to monitor for delayed renal involvement.

8. Is there a genetic component?
There is evidence of a genetic predisposition, but it is not typically inherited in a simple Mendelian pattern.

9. Can vaccines trigger IgA Vasculitis?
There are rare, documented cases of the condition following vaccination, but the benefits of vaccination far outweigh the risk, and the association is not causative in the majority of cases.

10. What is the standard treatment for joint pain in HSP?
Rest, hydration, and NSAIDs (like naproxen or ibuprofen) are usually effective. If NSAIDs are contraindicated due to renal issues, acetaminophen or short-course corticosteroids may be used.

9. Conclusion

Henoch-Schönlein Purpura (IgA Vasculitis) requires a multi-disciplinary approach. While the cutaneous presentation is often benign and self-limiting, the potential for silent, progressive renal damage necessitates diligent monitoring. Orthopedic and clinical specialists must be adept at recognizing the extra-cutaneous manifestations—specifically joint involvement and GI distress—to ensure timely intervention and prevent long-term systemic sequelae. Continued vigilance, particularly regarding urinalysis and blood pressure monitoring, remains the cornerstone of effective management in the clinical setting.